Kenvue

American consumer health company specializing in over-the-counter health and wellness products, spun off from Johnson & Johnson.

Company Type

public

Founded

2023

Headquarters

Jersey City, New Jersey, USA

Stock

NYSE: KVUE

About Kenvue

Kenvue is an American consumer health company founded in 2023 through a spin-off from Johnson & Johnson, headquartered in Jersey City, New Jersey. Under CEO Kirk Perry, Kenvue trades on NYSE (KVUE) and is the world's largest pure-play consumer health company by revenue. The company specializes in over-the-counter health and wellness products with iconic brands including Tylenol, Listerine, Band-Aid, and Neutrogena, reporting Q3 2025 net sales decline of 3.5% with adjusted diluted EPS of $0.28.

History of Kenvue

Kenvue was created in 2023 through a strategic spin-off from Johnson & Johnson, representing one of the most significant corporate restructurings in the consumer health industry. Johnson & Johnson separated its consumer health division to create an independent, focused company dedicated to over-the-counter health and wellness products, allowing both entities to concentrate on their respective core businesses and strategic priorities.

The spin-off was completed in August 2023, with Kenvue beginning operations as a standalone public company trading on the New York Stock Exchange under the ticker symbol KVUE. The company inherited a portfolio of well-known consumer health brands from Johnson & Johnson, including iconic names like Tylenol, Listerine, Band-Aid, Neutrogena, Aveeno, Motrin, Imodium, and Pepcid, which had been developed and marketed under Johnson & Johnson for decades.

Following the spin-off, Kenvue has focused on building its independent identity while maintaining the strength of its established brand portfolio. The company has invested significantly in innovation and product development for the consumer health market, leveraging its expertise in over-the-counter medications, personal care products, and wellness items to serve consumers globally.

Throughout late 2023 and 2024, Kenvue has established itself as an independent consumer health company competing in the over-the-counter market. The company has maintained strong market positions in pain relief, oral care, wound care, and skincare categories, benefiting from the brand recognition and consumer trust built over decades under Johnson & Johnson's stewardship.

In 2025, Kenvue appointed Kirk Perry as permanent Chief Executive Officer and announced additional key leadership appointments, strengthening the company's management team as it continued to build its independent corporate identity and strategic direction. Under Perry's leadership, the company has focused on four operating priorities to drive improved performance, including operational efficiency, brand innovation, market expansion, and digital transformation.

In the third quarter of 2025, Kenvue reported net sales decrease of 3.5% versus the prior year period, primarily reflecting organic sales decline of 4.4%, partially offset by foreign currency benefit of 1.0%. The company's gross profit margin expanded 60 basis points to 59.1% from 58.5% in the prior year period, with adjusted gross profit margin expanding 50 basis points to 61.2%, reflecting savings from productivity gains attributable to global supply chain optimization initiatives.

For the full year 2025, Kenvue affirmed its outlook with net sales and organic sales expected to be down low-single-digits, adjusted operating income margin expected to decline year-over-year, and adjusted diluted earnings per share expected to be in the range of $1.00 to $1.05, including a low-single-digit unfavorable impact from foreign currency. The company's performance demonstrates the challenges and opportunities of operating as an independent consumer health company in a competitive global market.

In 2026, Kenvue continues to operate as the world's largest pure-play consumer health company by revenue, leveraging its portfolio of iconic brands and global distribution network to serve consumers across multiple health and wellness categories. The company remains focused on executing its strategic priorities while navigating market challenges including competitive pressures, regulatory oversight, and changing consumer preferences in the over-the-counter health and wellness market.

Brands Owned by Kenvue

Kenvue owns 4 brands in our database.

Band-Aid

Owned by Kenvue

American brand of adhesive bandages and wound care products manufactured and marketed by Johnson & Johnson for minor cuts, scrapes, and injuries.

wound-careadhesive-bandagefirst-aid

Listerine

Owned by Kenvue

American antiseptic mouthwash brand known for its germ-killing formula and distinctive blue-green color, pioneering oral hygiene beyond brushing.

mouthwashantisepticoral-hygiene

Neutrogena

Owned by Kenvue

American brand of skincare products specializing in dermatologist-recommended cosmetics and treatments for various skin conditions.

skincaredermatologistacne

Tylenol

Owned by Kenvue

American brand of pain relief medication and analgesic drugs, flagship product of Kenvue Inc., the consumer health company spun off from Johnson and Johnson in 2023.

pain-reliefmedicationpharmaceutical

Shop Kenvue Brands

Disclosure: We may earn commission from purchases

Band-Aid on Amazon

Listerine on Amazon

Neutrogena on Amazon

Stock Information

Kenvue Ownership: Pros & Cons

Advantages

+Portfolio of well-established consumer health brands
+Strong market positions in multiple categories
+Global distribution network and retail presence
+Publicly traded allowing investor participation
+Focused business model on consumer health

Considerations

-Competition from other consumer health companies
-Regulatory oversight of over-the-counter products
-Market consolidation in consumer health sector
-Building independent company identity post-spin-off
-Pricing pressures and retail competition

Frequently Asked Questions About Kenvue

Who owns Kenvue?

Kenvue is owned by its public shareholders who trade the company's stock on the New York Stock Exchange under the ticker symbol KVUE. While Kenvue was spun off from Johnson & Johnson in 2023, it now operates as an independent, publicly traded company with no parent organization or controlling shareholder. Investors can purchase shares in Kenvue to gain exposure to the consumer health market and the company's portfolio of iconic over-the-counter brands.

Is Kenvue publicly traded?

Yes, Kenvue is publicly traded on the New York Stock Exchange under the ticker symbol KVUE. The company began trading as a standalone public company in May 2023 following its spin-off from Johnson & Johnson, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. The company was subsequently added to the S&P 500 Dividend Aristocrats index, reflecting its strong dividend-paying history and market position.

When was Kenvue founded?

Kenvue was founded in 2023 through a strategic spin-off from Johnson & Johnson. The spin-off was completed in August 2023, with Kenvue beginning operations as a standalone public company. The company was created to operate independently as a focused consumer health company, allowing Johnson & Johnson to concentrate on its pharmaceutical and medical device businesses while Kenvue focuses on over-the-counter health and wellness products.

Who is the CEO of Kenvue?

Kirk Perry serves as the Chief Executive Officer of Kenvue. Perry was named interim CEO in 2025 following the termination of previous CEO Thibaut Mongon, and was subsequently named as the permanent CEO in November 2025. Under Perry's leadership, Kenvue has focused on four operating priorities to drive improved performance: operational efficiency, brand innovation, market expansion, and digital transformation.

What does Kenvue manufacture?

Kenvue manufactures and markets over-the-counter health and wellness products across multiple categories including pain relief, oral care, wound care, skincare, digestive health, and allergy relief. The company's iconic brands include Tylenol (pain relief), Listerine (oral care), Band-Aid (wound care), Neutrogena (skincare), Aveeno (skincare), Motrin (pain relief), Imodium (digestive health), and Pepcid (digestive health), serving millions of consumers globally.

Where is Kenvue headquartered?

Kenvue is headquartered in Summit, New Jersey, USA, after relocating from the Skillman section of Montgomery Township, New Jersey. The company is incorporated in Delaware and maintains manufacturing facilities, research and development centers, and distribution networks across multiple countries including the United States, Europe, and Asia to support its global consumer health operations.

What is Kenvue's market position?

Kenvue holds the position of the world's largest pure-play consumer health company by revenue, with a portfolio of iconic over-the-counter brands that serve millions of consumers globally. The company maintains strong market positions in pain relief, oral care, wound care, and skincare categories, benefiting from decades of brand building and consumer trust established under Johnson & Johnson's stewardship.

What are Kenvue's recent achievements?

In 2025, Kenvue demonstrated operational efficiency improvements with Q3 gross profit margin expanding 60 basis points to 59.1% and adjusted gross profit margin expanding 50 basis points to 61.2%, reflecting savings from productivity gains attributable to global supply chain optimization initiatives. The company appointed Kirk Perry as permanent CEO and affirmed its full-year 2025 outlook with adjusted diluted earnings per share expected to be in the range of $1.00 to $1.05.

What are Kenvue's main brands?

Kenvue's portfolio includes iconic consumer health brands: Tylenol (pain relief and fever reduction), Listerine (oral care and mouthwash), Band-Aid (wound care and bandages), Neutrogena (skincare and personal care), Aveeno (skincare and personal care), Motrin (pain relief and anti-inflammatory), Imodium (digestive health), and Pepcid (digestive health). These brands represent one of the most comprehensive consumer health portfolios in the industry.

What is Kenvue's business outlook?

For the full year 2025, Kenvue affirmed its outlook with net sales and organic sales expected to be down low-single-digits, adjusted operating income margin expected to decline year-over-year, and adjusted diluted earnings per share expected to be in the range of $1.00 to $1.05, including a low-single-digit unfavorable impact from foreign currency. The company remains focused on executing its strategic priorities while navigating market challenges in the competitive global consumer health market.

About Kenvue

History of Kenvue